AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23128963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ibuprofen treatment)
Number of subjects: 36
Study 23128963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 36
Study 21778084 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper files with 30-gauge conventional dental needle
Number of subjects: 40
Study 21778084 — intervention group
Group type: EXPERIMENTAL
Intervention: RaCe files with 30-gauge conventional dental needle
Number of subjects: 40
Study 21778084 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper files with side-vented irrigation needle
Number of subjects: 40
Study 21778084 — intervention group
Group type: EXPERIMENTAL
Intervention: RaCe files with side-vented irrigation needle
Number of subjects: 40
Study 19034493 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided group
Number of subjects: 27
Study 19034493 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 16965418 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (four different types)
Number of subjects: 20
Study 16965418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cream base formulation)
Number of subjects: 20
Study 16965418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound
Number of subjects: 20
Study 16965418 — intervention group
Group type: EXPERIMENTAL
Intervention: Profilometry
Number of subjects: 20
Study 12723850 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic medications
Number of subjects: 0
Study 11248173 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative mortality risk estimation formula
Number of subjects: 134
Study 11248173 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative mortality risk estimation formula
Number of subjects: 134
Study 9240877 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (LT4) replacement therapy
Number of subjects: 44
Study 7506175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (50mg granules)
Number of subjects: 100
Study 7506175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (5 mg/kg/day)
Number of subjects: 100
Study 7506175 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (26 mg/kg/day)
Number of subjects: 100
Study 2896967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 562
Study 2896967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 562
Study 2896967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 562
Study 2896967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 2896967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato-bismuthate
Number of subjects: 562
Study 2896967 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 562
Study 2896967 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 562
Study 30300371 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (medication adjustment, stepped mental health care, exercise therapy)
Number of subjects: 168
Study 30300371 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 168
Study 30300371 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 168
Study 28665259 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (24 mg/day; 28-day cycle)
Number of subjects: 392
Study 28665259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 28665259 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 392
Study 26610844 — intervention group
Group type: COMPARATOR
Intervention: Tafenoquine regimen with three daily loading doses plus weekly maintenance at 200‐mg for 10 weeks or longer
Number of subjects: 492
Study 26610844 — intervention group
Group type: COMPARATOR
Intervention: Tafenoquine 200‐mg weekly
Number of subjects: 492
Study 26610844 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine 250‐mg weekly
Number of subjects: 492
Study 26610844 — intervention group
Group type: COMPARATOR
Intervention: Tafenoquine with a three‐day loading dose at 400‐mg
Number of subjects: 492
Study 26610844 — intervention group
Group type: COMPARATOR
Intervention: Tafenoquine with a three‐day loading dose at 400‐mg without follow-up weekly maintenance doses
Number of subjects: 492
Study 24282608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) before 5 years of age
Number of subjects: 42
Study 24282608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) after 5 years of age
Number of subjects: 42
Study 24282608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) with more than 5 years of implant use
Number of subjects: 42
Study 24282608 — intervention group
Group type: COMPARATOR
Intervention: Cochlear Implant (CI) regardless of age at implantation
Number of subjects: 42
Study 20499075 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clamping (<10 s post-delivery)
Number of subjects: 158
Study 20499075 — intervention group
Group type: COMPARATOR
Intervention: Delayed clamping (2 min post-delivery)
Number of subjects: 158
Study 18343056 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation in combination with hormone replacement therapy
Number of subjects: 0
Study 18343056 — intervention group
Group type: COMPARATOR
Intervention: Conventional postmenopausal hormone therapy
Number of subjects: 0
Study 17348310 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley's catheter alone
Number of subjects: 60
Study 17348310 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic instillation of Prostaglandin F-2 alpha (PGF2 alpha) via Foley's catheter
Number of subjects: 60
Study 14561238 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 20
Study 10971167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (20 mg/m(2)), Ifosfamide (1.5 g/m(2)), Irinotecan (60 mg/m(2)) with rhG-CSF support
Number of subjects: 18
Study 10971167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (15 mg/m(2)), Irinotecan (50 mg/m(2)) with rhG-CSF support (after dose adjustment)
Number of subjects: 18
Study 8840939 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic bicarbonate
Number of subjects: 0
Study 8840939 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 0
Study 8840939 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + bicarbonate
Number of subjects: 0
Study 8840939 — intervention group
Group type: COMPARATOR
Intervention: Insulin + saline
Number of subjects: 0
Study 8840939 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol + bicarbonate
Number of subjects: 0
Study 8840939 — intervention group
Group type: COMPARATOR
Intervention: Albuterol + saline
Number of subjects: 0
Study 8840939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate administration
Number of subjects: 0
Study 8840939 — intervention group
Group type: COMPARATOR
Intervention: Saline administration
Number of subjects: 0
Study 1473671 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 84
Study 1473671 — intervention group
Group type: COMPARATOR
Intervention: Control (no intravenous sedative)
Number of subjects: 84
Study 6387112 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intrauterine devices (IUDs)
Number of subjects: 0
Study 6387112 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intrauterine devices for postpartum use
Number of subjects: 0
Study 6387112 — intervention group
Group type: COMPARATOR
Intervention: Interval insertions of IUDs
Number of subjects: 0
Study 30764631 — intervention group
Group type: EXPERIMENTAL
Intervention: p16 positive tumors
Number of subjects: 49
Study 30764631 — intervention group
Group type: COMPARATOR
Intervention: p16 negative tumors
Number of subjects: 49
Study 30391274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity with blood flow restriction 'High' (LI + BFR_H)
Number of subjects: 56
Study 30391274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity with blood flow restriction 'Low' (LI + BFR_L)
Number of subjects: 56
Study 30391274 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity (HI)
Number of subjects: 56
Study 30391274 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 56
Study 30391274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity (LI)
Number of subjects: 56
Study 26490710 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation on complicated grief and helpful social support
Number of subjects: 0
Study 26490710 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation on complicated grief
Number of subjects: 0
Study 25305728 — intervention group
Group type: EXPERIMENTAL
Intervention: MACS (magnetic activated cell sorting) with swim-up preparation
Number of subjects: 237
Study 25305728 — intervention group
Group type: COMPARATOR
Intervention: Control group (swim-up preparation)
Number of subjects: 237
Study 21616737 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate, low-cost lifestyle intervention for diabetes prevention
Number of subjects: 0
Study 19854483 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% tramadol (2 mg/kg) plus adrenaline (0.0125/mL)
Number of subjects: 40
Study 19854483 — intervention group
Group type: COMPARATOR
Intervention: 2% prilocaine plus adrenaline (0.0125/mL)
Number of subjects: 40
Study 18076231 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% 1RM squat
Number of subjects: 16
Study 18076231 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% 1RM deadlift
Number of subjects: 16
Study 18076231 — intervention group
Group type: COMPARATOR
Intervention: Body weight squat, deadlift, superman, sidebridge
Number of subjects: 16
Study 15882280 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 30
Study 15882280 — intervention group
Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation
Number of subjects: 30
Study 12359778 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIV-T (first dose)
Number of subjects: 1314
Study 12359778 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIV-T (second dose)
Number of subjects: 1314
Study 12359778 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIV-T (year 2)
Number of subjects: 1314
Study 12359778 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIV-T (years 3 and 4)
Number of subjects: 1314
Study 12359778 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIV-T (between days 11 and 42)
Number of subjects: 1314
Study 12359778 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIV-T (years 1 to 4)
Number of subjects: 1314
Study 12359778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1314
Study 10426648 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 20 mg orally twice a day
Number of subjects: 49
Study 10426648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7760573 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 47
Study 7760573 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 47
Study 7760573 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror exposure with alcohol
Number of subjects: 47
Study 7760573 — intervention group
Group type: COMPARATOR
Intervention: Mirror exposure with placebo
Number of subjects: 47
Study 1969208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole shampoo, twice weekly for 4 weeks
Number of subjects: 36
Study 1969208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7286046 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg)
Number of subjects: 9
Study 7286046 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg) evening ingestion
Number of subjects: 9
Study 7286046 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg) morning ingestion
Number of subjects: 9
Study 30653305 — intervention group
Group type: EXPERIMENTAL
Intervention: Sand barrier latrines
Number of subjects: 68
Study 30653305 — intervention group
Group type: COMPARATOR
Intervention: Latrines without sand barriers
Number of subjects: 68
Study 27604762 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 48
Study 27604762 — intervention group
Group type: EXPERIMENTAL
Intervention: Brilliant blue G (BBG)
Number of subjects: 48
Study 27604762 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 48
Study 27604762 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 25885962 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information website (www.orthoanswer.org)
Number of subjects: 0
Study 25885962 — intervention group
Group type: COMPARATOR
Intervention: Standard discussion with the treating surgeon (Control)
Number of subjects: 0
Study 24099315 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 132
Study 24099315 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 132
Study 21285719 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy
Number of subjects: 0
Study 21285719 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical expulsive therapy with alpha-blockers
Number of subjects: 0
Study 18953506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant sodium selenite 0.2 mg kg(‐1) day(‐1) for 7 days in addition to chemotherapy
Number of subjects: 40
Study 18953506 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 40
Study 18953506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant sodium selenite
Number of subjects: 40
Study 17907391 — intervention group
Group type: COMPARATOR
Intervention: Manual Acupuncture (MA)
Number of subjects: 60
Study 17907391 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study 17907391 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 14982568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 10 mg of hyperbaric tetracaine with 0.2 mg of epinephrine (SE Group)
Number of subjects: 96
Study 14982568 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 10 mg of hyperbaric tetracaine (L Group)
Number of subjects: 96
Study 14982568 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 10 mg of hyperbaric tetracaine (S Group)
Number of subjects: 96
Study 14982568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine for bradycardia
Number of subjects: 96
Study 11172138 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of primary prophylaxis
Number of subjects: 587
Study 11172138 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of secondary prophylaxis
Number of subjects: 587
Study 9458381 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3-Receptor Antagonist (5-HT3-RA)
Number of subjects: 51
Study 9458381 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral metoclopramide (20 mg q.i.d.) + i.m. Dexamethasone (M + D)
Number of subjects: 51
Study 7931196 — intervention group
Group type: EXPERIMENTAL
Intervention: Model tasks with unique hiding places
Number of subjects: 0
Study 7931196 — intervention group
Group type: EXPERIMENTAL
Intervention: Model tasks with identical hiding places
Number of subjects: 0
Study 7931196 — intervention group
Group type: EXPERIMENTAL
Intervention: Model tasks with aligned models
Number of subjects: 0
Study 7931196 — intervention group
Group type: EXPERIMENTAL
Intervention: Model tasks with non-aligned models
Number of subjects: 0
Study 7931196 — intervention group
Group type: EXPERIMENTAL
Intervention: Model tasks for 5-year-olds
Number of subjects: 0
Study 2455099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA), 100 mg p.o./day plus tamoxifen (TAM), 100 mg p.o./day
Number of subjects: 0
Study 2455099 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (FLU), 750 mg p.o./day
Number of subjects: 0
Study 2455099 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 0
Study 2455099 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA plus TAM treated patients
Number of subjects: 0
Study 2455099 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU treated patients
Number of subjects: 0
Study 31855018 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Couples Intervention (TCI)
Number of subjects: 75
Study 31855018 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 75
Study 29703119 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Admission (BA)
Number of subjects: 8
Study 27982182 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite
Number of subjects: 32
Study 27982182 — intervention group
Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 32
Study 27982182 — intervention group
Group type: EXPERIMENTAL
Intervention: alkaline peroxide
Number of subjects: 32
Study 24434659 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.01%
Number of subjects: 60
Study 22538142 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-bevel pen needle (PN)
Number of subjects: 30
Study 21275333 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (15-35 minute session with live patient-preferred music and therapeutic social interaction)
Number of subjects: 58
Study 18162859 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-Therapy
Number of subjects: 1300
Study 17560638 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbal remedies
Number of subjects: 0
Study 17560638 — intervention group
Group type: COMPARATOR
Intervention: Conventional drugs (corticosteroids)
Number of subjects: 0
Study 14680665 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a randomized controlled trial
Number of subjects: 667
Study 14680665 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for nonparticipation
Number of subjects: 667
Study 11152170 — intervention group
Group type: EXPERIMENTAL
Intervention: CRM-induced skin responses and serum-specific IgE responses
Number of subjects: 100
Study 11152170 — intervention group
Group type: EXPERIMENTAL
Intervention: CRM-induced skin responses
Number of subjects: 100
Study 11152170 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum-specific IgE levels
Number of subjects: 100
Study 11152170 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum-specific IgG4 levels
Number of subjects: 100
Study 11152170 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum-specific IgG1 levels
Number of subjects: 100
Study 11152170 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of skin responses to CRM with serum-specific IgE levels
Number of subjects: 100
Study 11152170 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum CRM-specific IgE levels with specific IgG1 and IgG4 levels
Number of subjects: 100
Study 11152170 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between serum IgG1 and IgG4 levels
Number of subjects: 100
Study 9177986 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with omega‐3 and omega‐6 long‐chain polyunsaturated fatty acids and cholesterol (n = 12)
Number of subjects: 22
Study 9177986 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula (n = 10)
Number of subjects: 22
Study 9177986 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 8478475 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment for mature nodular port-wine stains, telangiectasia, small vascular lesions, and superficial pigmented lesions.
Number of subjects: 0
Study 3928674 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) at 50 micrograms/24 h and higher
Number of subjects: 0
Study 3928674 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) at 25, 50, 100, and 200 micrograms/24 h
Number of subjects: 0
Study 3928674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3928674 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2)
Number of subjects: 0
Study 29388413 — intervention group
Group type: EXPERIMENTAL
Intervention: Water swallowing
Number of subjects: 16
Study 29388413 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva swallowing
Number of subjects: 16
Study 29388413 — intervention group
Group type: EXPERIMENTAL
Intervention: Both swallowing tasks
Number of subjects: 16
Study 29927201 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose proton pump inhibitor (PPI) - intravenous pantoprazole 80 mg bolus then continuously drip 8 mg per hour
Number of subjects: 113
Study 29927201 — intervention group
Group type: COMPARATOR
Intervention: Standard dose proton pump inhibitor (PPI) - intravenous pantoprazole 40 mg twice daily
Number of subjects: 113
Study 29927201 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose proton pump inhibitor (PPI)
Number of subjects: 113
Study 29927201 — intervention group
Group type: COMPARATOR
Intervention: Standard dose proton pump inhibitor (PPI)
Number of subjects: 113
Study 24118885 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7687 (1, 2.5, 5, 10 and 20 mg/day)
Number of subjects: 62
Study 24118885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24118885 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7687 (doses >5 mg/day)
Number of subjects: 62
Study 22090395 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0929
Number of subjects: 0
Study 22090395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20409605 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN)
Number of subjects: 250
Study 20409605 — intervention group
Group type: COMPARATOR
Intervention: Logistic models
Number of subjects: 250
Study 18331385 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 1868
Study 18331385 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein thresholds (40, 60, 120 mg/l)
Number of subjects: 1868
Study 18331385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of raised CRP concentration with clinical diagnosis of pneumonia
Number of subjects: 1868